Eureka Therapeutics, Inc. develops therapeutic monoclonal antibodies for cancer indication and treatment. It focuses on the discovery of fully-human antibody drugs for the treatment of cancer and utilizing its antibody drug discovery and engineering technologies, and advancing therapies for targeting previously inaccessible cancer antigens. The company was founded by Cheng Liu in 2006 and is headquartered in Emeryville, CA.

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

Xiangxue Life Science Technology (Guangdong) Co., Ltd., established on 2020-12-23, Business scope includes general items:R&D and application of cell technology;Medical Research and Experimental Development;Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Technology Import and Export;Import and export.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license).licensed items:Drug import and export;pharmaceutical production.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments).

Attobio Pharmaceutical (Suzhou) Co. Ltd. engages in the development of biomedical technology and products. Its business activities include the innovation of products designed to improve the level of preventive medicine and early detection of disease to provide accurate diagnostic techniques, and the import and export of biological reagents and biotechnology. The company was founded by Xiao Jia Chang on May 7, 2012 and is headquartered in Suzhou, China.

Editas Medicine is engaged in discovering and developing a novel class of genome editing therapeutics. The company has generated substantial patent filings and has access to intellectual property covering foundational genome editing technologies, as well as essential advancements and enablements that will uniquely allow the company to translate early findings into viable human therapeutic products. Editas Medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level. It was founded in 2013 and is headquartered in Cambridge, Massachusetts, the United States with a growing site in Boulder, Colorado.

Tianjin Best Biotech Co., Ltd., established on 2010-12-20, Business scope includes general items:Technical Services,technology development,technical consulting,Technology Exchange,technology transfer,Technology Promotion;Research and development of bio-based materials technology;Disinfectant sales(Free of Hazardous Chemicals);Sales of Class I Medical Devices;Sales of Class II Medical Devices;Personal Hygiene Sales;Sales of hygiene products and single-use medical products;Sales of formula food for special medical purposes.(Except for projects subject to approval by law,Carry out business activities independently in accordance with the law with a business license)licensed items:food sales;Production of disinfection products for the prevention and control of infectious diseases[Branch operation].(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments,The specific business items are subject to the approval documents or licenses of relevant departments)

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

IDEC Pharmaceuticals develop therapies for the treatment of neurodegenerative, hematologic, and autoimmune diseases. Idec Pharmaceuticals was founded in 1986 by UC-San Diego physician and immunologist Ivor Royston, San Diego bioentrepreneur Howard Birndorf, and Stanford University cancer researchers Ron Levy and Richard Miller. In 2003, Idec Pharmaceuticals was merged with Biogen.

Bozhou New Health Technology Co., Ltd., established on 2015-12-18, The business scope includes the production and sales of medical devices;Production and sales of disinfection products;Wholesale of medical equipment(one type,Class II,Three categories);Experimental Research and Development of Medical Technology;Marketing of pharmaceutical and medical device products,academic promotion,Marketing Planning,Market Research Services;Self-operated and agent import and export business of various commodities and technologies(Except for commodities and technologies that the state restricts enterprises to operate or prohibits import and export).(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Develops and manufactures drugs related to immunology, neurobiology and oncology

Qingdao Haier Biotechnology Co., Ltd., established on 2018-07-27, Business scope includes technology development in the field of biotechnology,consult,Transfers and Services;collection of cells,storage,Preparation and related technology development and application;Development, research and application of genetic testing and disease screening;Research and development of biotechnology equipment and instruments, their parts and consumables,production and sales;Medical service;computer technology development,Technical Services;Technology Import and Export;trade agent;Cosmetics research and development and sales.(Items subject to approval by law,Business activities can only be carried out after approval by relevant departments)

Calliditas Therapeutics France SAS is a biopharmaceutical company that develops NOX therapies. Its therapeutic approach is based on a selective inhibition of NOX enzymes that amplify multiple disease processes, such as fibrosis, inflammation, pain processing, cancer development, and eurodegeneration. The company's platform enables the identification of orally available small-molecules that selectively inhibit specific NOX enzymes. The company's product candidate, setanaxib, a NOX1 and NOX4 inhibitor, demonstrated clinical evidence of anti-fibrotic activity in liver fibrosis patients in a phase II trial in primary biliary cholangitis. Genkyotex was founded in 2006 and is headquartered in Saint-Julien-en-Genevois, France.

Shenzhen Inno Immunization Co., Ltd., established on 2016-07-08, Business scope includes general business items:Biotechnology research and development and application promotion(Does not contain national restrictions and prohibited items,involving special regulations,Operate only after obtaining the relevant license),biotechnology transfer,Technical service and technical consultation(No restrictions on foreign investment,Prohibited items);Goods and technology import and export business(Excluding import distribution,National exclusive control of goods);Wholesale of Class I Medical Devices.,The licensing program is:

Flemed Biomedical Technology (Tianjin) Co., Ltd., established on 2014-05-23, Business scope includes biomedical technology research and development,consult,Serve,transfer;medical instruments,Biopharmaceutical Manufacturing;Wholesale of medical equipment;Instrumentation,chemical reagent(dangerous goods,Flammable and explosive products,Precursor Drugs Excluded),Wholesale of chemical raw materials,Retail and Import and Export;Trade Agency Services.(Enterprises independently choose operating projects according to law,Carry out business activities;Items subject to approval by law,Carry out business activities in accordance with the approved content after approval by relevant departments)

Zhuhai Meihua Medical Technology Co. Ltd. is a company headquartered in Zhuhai, China, specializing in measuring and controlling devices. It was founded in 2007.

Nykode Therapeutics ASA is a clinical-stage biopharmaceutical company which engages in discovering and developing of novel immunotherapies. It focuses on developing field of individualized cancer neoantigen vaccines by using the Vaccibody technology to generate therapeutics to treat cancer. The company was founded by Inger Sandlie and Agnete Brunsvik Fredriksen on November 22, 2006 and is headquartered in Oslo, Norway.

DKFZ Deutsche Krebsforschungszentrum is a German private company that operates as a cancer research center.